挖掘差距:通过人工智能驱动的和解解读阿尔茨海默病的生物学
Cory C Funk1, Tom Paterson2, Alex Bangs2
1Institute for Systems Biology, Seattle WA; Fulcrum Neuroscience, Palo Alto, CA.
The journal of prevention of Alzheimer's disease
|December 1, 2025
概括
人工智能 (AI) 通过协调碎片化数据和假设,为阿尔茨海默病研究提供了一种新的方法. 这种人工智能驱动的和解旨在创建连贯的模型来理解和治疗阿尔茨海默病.
科学领域:
- 生物医学是生物医学.
- 人工智能的人工智能
- 神经退行性疾病 神经退行性疾病
背景情况:
- 阿尔茨海默病的研究是复杂的,有碎片化的发现和竞争的假设.
- 有限的翻译成功阻碍了对疾病的理解和治疗的进展.
研究的目的:
- 提出人工智能作为在阿尔茨海默病研究中认识论和解的工具.
- 将不同的数据,方法和机制见解整合到连贯的模型中.
- 在理解阿尔茨海默病的出现,进展和治疗方面改变范式.
主要方法:
- 利用人工智能进行和解,而不仅仅是预测性能.
- 开发灵活,可测试的数字双胞胎架构,以恒常和多尺度连贯为基础.
- 采用代的,可互操作的AI架构来整合证据和解决矛盾.
主要成果:
- 人工智能有助于调整各种数据和机械洞察力.
- 数字双胞胎可以作为可测试的架构来理解疾病动态.
- 这种方法突出了阿尔茨海默病研究中的关键知识缺口.
结论:
- 人工智能驱动的和解为阿尔茨海默病研究提供了一个范式转变.
- 这一框架超越了渐进的进步,转变了科学理解和应用.
- 和解被提出为推动阿尔茨海默病科学发展的指导原则.
更多相关视频
06:46Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
12.7K
04:41Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration
Published on: January 9, 2020
19.3K
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
764
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
764
